Dr Christopher Ting is currently Group CEO of Pathology Asia Holdings (PAH) which he co-founded with TPG. PAH is a S.E Asian focused, medical diagnostics network operating across Australia, Malaysia, Singapore and Vietnam. PAH is the largest and most awarded multi-disciplinary medical laboratory network across Singapore and Malaysia. Dr Ting is an entrepreneur and investor with a 24 year track in the healthcare industry and has led turnarounds, grown companies through M&A, as well as built businesses ground up from start-up to successful exits. Dr Ting has a passion for medical technology and data science and is currently a director or founder at a number of healthcare and medtech companies. He previously headed ASX listed Healthscope Ltd’s pathology assets in S.E Asia and grew them into leading positions in their respective countries. His career has also included roles at the Economic Development Board, Singapore and as CEO of a hospital after leading its buyout. He was a clinician in Australia for 5 years. He received his medical degree from the University of Melbourne and his MBA from Melbourne Business School.